PAH Initiative, transforming knowledge into patient care

PAH Initiative: A resource to help healthcare providers treat adult patients with PAH

The PAH Initiative, sponsored by United Therapeutics, is committed to providing information and resources to assist HCPs in providing care and treatment for those impacted by pulmonary arterial hypertension (PAH). Whether you occasionally see patients with PAH, or you are a dedicated PAH specialist, the PAH Initiative provides clinically useful information and practical tools to help you improve the lives of your patients with PAH.

On this website, you will find:

  • Information on the diagnosis and treatment of PAH
  • An in-depth discussion on the pathophysiology of PAH
  • Data showing the importance of risk assessment in determining prognosis
  • Risk calculators to assess the risk status of patients
  • Information on treatment approaches
  • Resources including podcasts by experts in PAH, recent publications about PAH, and more

Improving risk status is today's treatment goal

PAH is a complex, progressive disease where high blood pressure in the lungs eventually causes right heart failure.1 As the understanding of PAH has evolved, patient management and care have also evolved. Twenty-five years ago, parenteral prostacyclin therapy was the only PAH-specific medication available.2 Now, there are at least 12 medications available to treat 3 disease pathways. Medications are also available in 3 formulations—parenteral, inhaled, and oral—making it easier to treat earlier.2,3

Recently, risk assessment to determine initial therapy and appropriate treatment escalation has become the standard of care for patients with PAH. Treatment guidelines now recommend that most patients should start with and receive combination therapy with at least 2 PAH medications4; monotherapy has a residual role in initial treatment.4

In addition to addressing general health and supportive care considerations, PAH risk assessment and early intervention with appropriate PAH medications are critical to improving outcomes in patients.4 According to the latest PAH treatment guidelines, you should:

  • Assess risk status at diagnosis of PAH and at 3- to 6-month intervals afterward to help inform treatment decisions4
  • Target multiple pathogenic pathways (nitric oxide, prostacyclin, endothelin) using a combination of medications, as recommended by treatment guidelines4
  • Aim for low-risk status to help improve your patients' prognosis4

No matter your familiarity with PAH, the PAH Initiative provides tools and resources designed to broaden your understanding of PAH. The goal is to enable you to help your patients feel better today with the goal of improving their prognosis.

Calculate risk quickly

The PAH Initiative offers online access to risk calculation tools and EHR instructions. Choose among 4 risk calculators, including the REVEAL Lite 2 calculator.

Find recent publications

Stay up-to-date on the best practices in PAH monitoring and treatment.

What do the PAH treatment guidelines say?

Initial combination therapy is advised for most patients upon diagnosis, and risk assessments every 3 to 6 months are needed to help your patients aim for and achieve low-risk status.4

Review Guidelines

Why is routine risk assessment necessary?

Assessing risk status aids in the determination of prognosis, initial therapy choice, response to therapy, and the need for adjustments to treatment.4

Integrate Risk Assessment

When is it time for another medication?

Even FC II patients may need their treatment escalated to achieve low-risk status.4,5

Treat Multiple Pathways
Is your FC II patient low risk article thumbnail

Is your FC II patient low risk?

A peer-reviewed article by Dr. Sandeep Sahay shows that even patients with PAH who are categorized as FC II can be at increased risk for hospitalization or death.5

Download Article (PDF)
PAH Care Today Podcast 3 of 4 with Raymond Benza, MD and Vallerie Mclaughlin, MD on Therapy Escalation

Podcast: Listen to expert insights into optimizing patient outcomes

Dr. Raymond Benza and Dr. Vallerie McLaughlin discuss how to clinically apply risk status to escalate therapy and improve patient prognosis.

Listen Now

Do you have REVEAL 2.0 in your Epic EHR?

EHR instructions provide direction on implementing the REVEAL 2.0 calculator in Epic.

Get Instructions
PAH Initiative patient education materials questionnaire thumbnail

Find patient education materials

Enhance the experience for your patients with a waiting room checklist, risk assessment handout, and other resources.

View Resources
EHR=electronic health record; FC=Functional Class; HCP=healthcare practitioner.References: 1. Gaine S, et al. Eur Respir Rev. 2017;26(146):170095. 2. Lajoie AC, et al. Pulm Circ. 2017;7(2):312-325. 3. Galiè N, et al. Eur Heart J. 2016;37(1):67-119. 4. Galiè N, et al. Eur Respir J. 2019;53(1):1801889. 5. Sahay S, et al. PLoS One. 2020;15(11):e0241504.